CB1/Cannabinoid Receptor 1/CNR1 Antibody (2F9): sc-293419

CB1 Antibody (2F9) is a mouse monoclonal IgG2b kappa light chain antibody that detects CB1 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). Anti-CB1 antibody (2F9) is available as a non-conjugated format. CB1, also known as cannabinoid receptor 1, is a G-protein coupled receptor predominantly expressed in the brain, where CB1 plays a crucial role in modulating neurotransmitter release and influencing various physiological processes. CB1 localization in the central nervous system is particularly important as CB1 is involved in the regulation of pain, mood, appetite, and memory, making CB1 a significant target for therapeutic interventions in conditions such as chronic pain, anxiety, and neurodegenerative diseases. CB1 undergoes post-translational modifications, including phosphorylation, which can affect CB1 activity and interactions with other proteins. Phosphorylation at serine 316 disrupts CB1 -mediated inhibition of calcium channels, thereby influencing neuronal excitability and signaling pathways. This intricate regulation underscores CB1 importance in maintaining homeostasis within the nervous system and highlights CB1 potential as a target for drug development aimed at modulating cannabinoid effects.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CB1/Cannabinoid Receptor 1/CNR1 Antibody (2F9) References:

1. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells.  |  Sugiura, T., et al. 2000. J Biol Chem. 275: 605-12. PMID: 10617657
2. The endogenous cannabinoid system and brain development.  |  Fernández-Ruiz, J., et al. 2000. Trends Neurosci. 23: 14-20. PMID: 10631784
3. Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors.  |  Valverde, O., et al. 2000. Eur J Neurosci. 12: 533-9. PMID: 10712632
4. Molecular cloning of a human cannabinoid receptor which is also expressed in testis.  |  Gérard, CM., et al. 1991. Biochem J. 279 (Pt 1): 129-34. PMID: 1718258
5. Development of radioligands for in vivo imaging of type 1 cannabinoid receptors (CB1) in human brain.  |  Horti, AG. and Van Laere, K. 2008. Curr Pharm Des. 14: 3363-83. PMID: 19075713
6. Signal transduction of the CB1 cannabinoid receptor.  |  Turu, G. and Hunyady, L. 2010. J Mol Endocrinol. 44: 75-85. PMID: 19620237
7. Structure of a cannabinoid receptor and functional expression of the cloned cDNA.  |  Matsuda, LA., et al. 1990. Nature. 346: 561-4. PMID: 2165569
8. Cannabinoid CB1 Receptor Deletion from Catecholaminergic Neurons Protects from Diet-Induced Obesity.  |  Srivastava, RK., et al. 2022. Int J Mol Sci. 23: PMID: 36293486
9. Molecular characterization of a peripheral receptor for cannabinoids.  |  Munro, S., et al. 1993. Nature. 365: 61-5. PMID: 7689702
10. Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor.  |  Shire, D., et al. 1996. Biochim Biophys Acta. 1307: 132-6. PMID: 8679694
11. Protein kinase C disrupts cannabinoid actions by phosphorylation of the CB1 cannabinoid receptor.  |  Garcia, DE., et al. 1998. J Neurosci. 18: 2834-41. PMID: 9526000
12. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice.  |  Ledent, C., et al. 1999. Science. 283: 401-4. PMID: 9888857

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CB1/Cannabinoid Receptor 1/CNR1 Antibody (2F9) has 13 citations in a variety of scientific publications.

Primary antibodies like Anti-CB1/Cannabinoid Receptor 1/CNR1 Antibody (2F9) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CB1/Cannabinoid Receptor 1/CNR1 Antibody (2F9) Specifications

Alternate Product Name: CB1

Product Clone Name: 2F9

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2b kappa light chain

Amino Acids: 1-110

Epitope Target: CB1

Epitope Species: human

Product Reactivity/Detection: CB1

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, ELISA

Vialing Information: Each vial contains 100 µg IgG_2b kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 13 citations in various scientific publications

Available Conjugates/Forms for CB1/Cannabinoid Receptor 1/CNR1 Antibody (2F9): N/A

The preferred CB1/Cannabinoid Receptor 1/CNR1 antibody is CB1/Cannabinoid Receptor 1/CNR1 Antibody (C-11): sc-518035.